Rattanapan Yanisa, Nongwa Kallayarat, Supanpong Chanoknan, Satsadeedat Chanasorn, Sai-Ong Thaveesak, Kooltheat Nateelak, Chareonsirisuthigul Takol
Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat, Thailand.
Hematology and Transfusion Science Research Center, Walailak University, Nakhon Si Thammarat, Thailand.
J Clin Med Res. 2024 Dec;16(11):536-546. doi: 10.14740/jocmr6099. Epub 2024 Nov 30.
This study is designed to investigate the differential microRNA (miRNA) expression profiles in individuals with and without type 2 diabetes mellitus (T2DM). The focus is on miRNAs that play a crucial role in the onset and progression of T2DM, particularly in glucose metabolism, inflammation, platelet reactivity, and endothelial dysfunction.
Twenty samples were categorized into groups of T2DM and non-T2DM, and miRNA profiling was conducted using microarray analysis. The expression levels of the candidate , as well as its target genes platelet-activating factor receptor () and insulin-like growth factor 2 mRNA binding protein 3 (), were validated using quantitative polymerase chain reaction (qPCR).
The present study revealed a significant reduction in the level of in the T2DM group compared to the non-T2DM group. This suggests higher levels of and in individuals with T2DM, indicating a potential biomarker for the condition.
The downregulation of , which is associated with increased levels, may contribute to heightened platelet reactivity and inflammation, worsening endothelial dysfunction, and potentially influencing vascular complications in diabetes. Additionally, the upregulation of is correlated with insulin resistance and β-cell dysfunction, which may contribute to elevated hyperglycemia and hyperinsulinemia, further aggravating the progression of diabetes. These findings highlight the potential of and as biomarkers for T2DM and suggest their possible relevance for improving diagnosis and treatment strategies.
本研究旨在调查2型糖尿病(T2DM)患者与非T2DM患者之间微小RNA(miRNA)表达谱的差异。重点关注在T2DM发病和进展中起关键作用的miRNA,特别是在葡萄糖代谢、炎症、血小板反应性和内皮功能障碍方面。
将20个样本分为T2DM组和非T2DM组,采用微阵列分析进行miRNA谱分析。使用定量聚合酶链反应(qPCR)验证候选miRNA及其靶基因血小板活化因子受体(PAFR)和胰岛素样生长因子2 mRNA结合蛋白3(IGF2BP3)的表达水平。
本研究显示,与非T2DM组相比,T2DM组中某miRNA水平显著降低。这表明T2DM患者中另外两种miRNA水平较高,提示其可能为该病的生物标志物。
与另外两种miRNA水平升高相关的某miRNA下调可能导致血小板反应性和炎症加剧,内皮功能障碍恶化,并可能影响糖尿病的血管并发症。此外,另一种miRNA的上调与胰岛素抵抗和β细胞功能障碍相关,这可能导致高血糖和高胰岛素血症升高,进一步加重糖尿病的进展。这些发现凸显了这两种miRNA作为T2DM生物标志物的潜力,并表明它们可能与改善诊断和治疗策略相关。